Literature DB >> 21057041

Multiple splicing defects caused by hERG splice site mutation 2592+1G>A associated with long QT syndrome.

Matthew R Stump1, Qiuming Gong, Zhengfeng Zhou.   

Abstract

Long QT syndrome type 2 (LQT2) is caused by mutations in the human ether-a-go-go-related gene (hERG). Cryptic splice site activation in hERG has recently been identified as a novel pathogenic mechanism of LQT2. In this report, we characterize a hERG splice site mutation, 2592+1G>A, which occurs at the 5' splice site of intron 10. Reverse transcription-PCR analyses using hERG minigenes transfected into human embryonic kidney-293 cells and HL-1 cardiomyocytes revealed that the 2592+1G>A mutation disrupted normal splicing and caused multiple splicing defects: the activation of cryptic splice sites within exon 10 and intron 10 and complete intron 10 retention. We performed functional and biochemical analyses of the major splice product, hERGΔ24, in which 24 amino acids within the cyclic nucleotide binding domain of the hERG channel COOH-terminus is deleted. Patch-clamp experiments revealed that the splice mutant did not generate hERG current. Western blot and immunostaining studies showed that mutant channels did not traffic to the cell surface. Coexpression of wild-type hERG and hERGΔ24 resulted in significant dominant-negative suppression of hERG current via the intracellular retention of the wild-type channels. Our results demonstrate that 2592+1G>A causes multiple splicing defects, consistent with the pathogenic mechanisms of long QT syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21057041      PMCID: PMC3023262          DOI: 10.1152/ajpheart.00818.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  31 in total

Review 1.  Quality control of eukaryotic mRNA: safeguarding cells from abnormal mRNA function.

Authors:  Olaf Isken; Lynne E Maquat
Journal:  Genes Dev       Date:  2007-08-01       Impact factor: 11.361

2.  Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism.

Authors:  Corey L Anderson; Brian P Delisle; Blake D Anson; Jennifer A Kilby; Melissa L Will; David J Tester; Qiuming Gong; Zhengfeng Zhou; Michael J Ackerman; Craig T January
Journal:  Circulation       Date:  2006-01-24       Impact factor: 29.690

3.  EuSplice: a unified resource for the analysis of splice signals and alternative splicing in eukaryotic genes.

Authors:  Ashwini Bhasi; Ram Vinay Pandey; Suriya Prabha Utharasamy; Periannan Senapathy
Journal:  Bioinformatics       Date:  2007-03-07       Impact factor: 6.937

Review 4.  A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance.

Authors:  E Nagy; L E Maquat
Journal:  Trends Biochem Sci       Date:  1998-06       Impact factor: 13.807

5.  C-terminal HERG mutations: the role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence.

Authors:  M Berthet; I Denjoy; C Donger; L Demay; H Hammoude; D Klug; E Schulze-Bahr; P Richard; H Funke; K Schwartz; P Coumel; B Hainque; P Guicheney
Journal:  Circulation       Date:  1999-03-23       Impact factor: 29.690

6.  Nonsense mutations in hERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA decay in human long-QT syndrome.

Authors:  Qiuming Gong; Li Zhang; G Michael Vincent; Benjamin D Horne; Zhengfeng Zhou
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

7.  A KCNH2 branch point mutation causing aberrant splicing contributes to an explanation of genotype-negative long QT syndrome.

Authors:  Lia Crotti; Marzena A Lewandowska; Peter J Schwartz; Roberto Insolia; Matteo Pedrazzini; Erica Bussani; Federica Dagradi; Alfred L George; Franco Pagani
Journal:  Heart Rhythm       Date:  2008-11-06       Impact factor: 6.343

8.  A splice site mutation in hERG leads to cryptic splicing in human long QT syndrome.

Authors:  Qiuming Gong; Li Zhang; Arthur J Moss; G Michael Vincent; Michael J Ackerman; Jeffrey C Robinson; Melanie A Jones; David J Tester; Zhengfeng Zhou
Journal:  J Mol Cell Cardiol       Date:  2008-01-17       Impact factor: 5.000

9.  Recurrent intrauterine fetal loss due to near absence of HERG: clinical and functional characterization of a homozygous nonsense HERG Q1070X mutation.

Authors:  Zahurul A Bhuiyan; Tarek S Momenah; Qiuming Gong; Ahmad S Amin; Saleh Al Ghamdi; Julene S Carvalho; Tessa Homfray; Marcel M A M Mannens; Zhengfeng Zhou; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2008-01-29       Impact factor: 6.343

10.  Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice.

Authors:  Carlo Napolitano; Silvia G Priori; Peter J Schwartz; Raffaella Bloise; Elena Ronchetti; Janni Nastoli; Georgia Bottelli; Marina Cerrone; Sergio Leonardi
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

View more
  4 in total

1.  LQT2 nonsense mutations generate trafficking defective NH2-terminally truncated channels by the reinitiation of translation.

Authors:  Matthew R Stump; Qiuming Gong; Zhengfeng Zhou
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-08-30       Impact factor: 4.733

Review 2.  Translational toxicology and rescue strategies of the hERG channel dysfunction: biochemical and molecular mechanistic aspects.

Authors:  Kai-ping Zhang; Bao-feng Yang; Bao-xin Li
Journal:  Acta Pharmacol Sin       Date:  2014-11-24       Impact factor: 6.150

3.  Early LQT2 nonsense mutation generates N-terminally truncated hERG channels with altered gating properties by the reinitiation of translation.

Authors:  Matthew R Stump; Qiuming Gong; Jonathan D Packer; Zhengfeng Zhou
Journal:  J Mol Cell Cardiol       Date:  2012-09-03       Impact factor: 5.000

4.  Isoform-specific dominant-negative effects associated with hERG1 G628S mutation in long QT syndrome.

Authors:  Matthew R Stump; Qiuming Gong; Zhengfeng Zhou
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.